Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: semaglutide
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified August 2016

Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone

Condition:   Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Interventions:   Drug: Ipragliflozin;   Drug: metformin with pioglitazone
Sponsor:   Yonsei University
Recruiting - verified August 2016

Effect of Valedia on Glucose and Lipid Homeostasis on Subjects With Prediabetes

Conditions:   Prediabetes;   Type 2 Diabetes;   Hypertriglyceridemia;   Obesity;   Disease;   Insulin Resistance
Interventions:   Dietary Supplement: Valedia;   Dietary Supplement: Placebo
Sponsors:   Valbiotis;   BioFortis
Recruiting - verified August 2016

Brief Intervention to Promote Smoking Cessation in DM Smokers

Condition:   Smoking
Interventions:   Behavioral: Smoking cessation and DM specific component intervention;   Behavioral: Control group
Sponsor:   The University of Hong Kong
Completed - verified August 2016

Genetic Markers and Proliferative Diabetic Retinopathy

Condition:   Proliferative Diabetic Retinopathy
Intervention:   Genetic: genetic analysis
Sponsor:   CHU de Reims
Recruiting - verified August 2016

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Obese;   Overweight
Interventions:   Radiation: Gastric Emptying test;   Other: Mixed Oral Glucose Tolerance test;   Drug: Conjugated bile acids sodium;   Other: Placebo
Sponsors:   Mayo Clinic;   Satiogen Pharmaceuticals, Inc.
Not yet recruiting - verified June 2016

Anti-inflammatory Effects of the Fiber

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: dietary fiber
Sponsor:   University at Buffalo
Recruiting - verified August 2016

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: empagliflozin
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2016

Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2016

Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Low intensity therapeutic ultrasound
Sponsor:   Universidade Federal de Santa Maria
Not yet recruiting - verified August 2016

Effect of DMR Using the Revita System in the Treatment of Type 2 Diabetes (T2D)

Conditions:   Diabetes Mellitus, Type 2;   Noninsulin-Dependent Diabetes Mellitus
Interventions:   Procedure: DMR Procedure;   Procedure: Sham Procedure
Sponsor:   Fractyl Laboratories, Inc.
Not yet recruiting - verified August 2016

CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea

Conditions:   Diabetic Retinopathy;   Sleep Apnea
Interventions:   Device: Continuous positive airway pressure;   Drug: Pharmacological treatment;   Other: Conventional anti-diabetic diet recommendations
Sponsor:   Hospital Universitario La Paz
Recruiting - verified August 2016

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Drug: Insulin glargine;   Drug: Non-insulin antihyperglycemic drugs
Sponsor:   Sanofi
Recruiting - verified August 2016

FM-SRP and Tooth Extraction Improve Type 2 Diabetes Mellitus in Periodontitis

Conditions:   Periodontitis;   Type 2 Diabetes Mellitus
Interventions:   Procedure: Surgical Periodontal Treatment;   Device: Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.;   Drug: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
Sponsors:   University Clinical Centre of Kosova;   University of Ljubljana, Faculty of Medicine
Recruiting - verified August 2016

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Condition:   SIADH
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   University Hospital, Basel, Switzerland
Enrolling by invitation - verified August 2016

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2016

Influence of Central Nervous Insulin Sensitivity on Insulin Secretion

Condition:   Insulin Secretion
Interventions:   Drug: intranasal insulin;   Drug: Placebo
Sponsor:   University Hospital Tuebingen
Recruiting - verified August 2016

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ipragliflozin
Sponsor:   Astellas Pharma Inc
Recruiting - verified August 2016

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified August 2016

HbA1c Variability in Type II Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Metformin;   Drug: Gliclazide;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Pioglitazone;   Drug: Dapagliflozin;   Drug: human insulin
Sponsors:   Weill Cornell Medical College in Qatar;   Hamad Medical Corporation;   Sidra Medical and Research Center;   University of Hull
Not yet recruiting - verified August 2016

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2016

The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis

Conditions:   Rheumatoid Arthritis;   Physical Activity
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Siobhan Graham;   University of Bath
Active, not recruiting - verified August 2016

FreeStyle Libre- Effect on QOL in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Device: FreeStyle Libre;   Device: personal glucometer
Sponsor:   Wolfson Medical Center
Not yet recruiting - verified August 2016

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin IR
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2016

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified August 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified August 2016

PASS to Assess Risk of Renal Injury, Hepatic Injury and Infections in Empagliflozin-treated Patients

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)

Conditions:   Coronary Heart Disease;   Metabolic Syndrome;   Diabetes Mellitus
Interventions:   Radiation: PET scan;   Radiation: Echocardiogram
Sponsors:   Brigham and Women's Hospital;   Ottawa Heart Institute Research Corporation;   University of Alabama at Birmingham
Recruiting - verified August 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified August 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified August 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified August 2016

Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training

Conditions:   Exercise;   Chemotherapy-induced Polyneuropathy
Intervention:   Behavioral: Exercise
Sponsors:   German Cancer Research Center;   University Hospital Heidelberg;   National Center for Tumor Diseases, Heidelberg
Recruiting - verified August 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified August 2016

A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema

Conditions:   Diabetes Mellitus;   Diabetic Retinopathy;   Diabetic Macular Edema
Intervention:  
Sponsor:   Queen's University, Belfast
Recruiting - verified August 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2016

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin placebo
Sponsors:   AstraZeneca;   Parexel;   Q2 solutions;   PRA Health Sciences;   Covance Laboratories, Inc
Recruiting - verified August 2016

Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases

Conditions:   Diabetes Mellitus, Type 2;   Metabolic Syndrome X;   Hypertension;   Cardiovascular Diseases;   Stroke;   Gout
Intervention:   Other: Fructose-containing Sugars
Sponsors:   University of Toronto;   Canadian Institutes of Health Research (CIHR);   The Physicians' Services Incorporated Foundation;   Canadian Diabetes Association (CDA)
Active, not recruiting - verified May 2016

Effect of D-allulose in Addition to Oral Sucrose Load

Condition:   Blood Glucose
Interventions:   Dietary Supplement: D-allulose;   Dietary Supplement: sucrose;   Other: Placebo
Sponsor:   University of Florida
Recruiting - verified August 2016

The Effect of Dopamine on Diabetic Retinopathy

Condition:   Diabetes
Interventions:   Drug: Low Dose Sinemet CR;   Drug: High Dose Sinemet CR;   Device: RETeval Electroretinogram (ERG) Testing;   Other: Contrast Sensitivity Testing;   Other: Visual Acuity Testing
Sponsor:   Emory University
Recruiting - verified August 2016

Families Preventing Diabetes Together

Conditions:   Type 2 Diabetes;   Pediatric Obesity
Intervention:   Behavioral: Families Preventing Diabetes Together
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting - verified August 2016

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Recruiting - verified August 2016

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

Condition:   Type 2 Diabetes Mellitus.
Interventions:   Drug: DS-8500a 25 mg;   Drug: DS-8500a 75 mg;   Drug: placebo
Sponsors:   Daiichi Sankyo Co., Ltd.;   Mediscience Planning, Inc.
Active, not recruiting - verified August 2016

Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects

Condition:   Diabetes
Interventions:   Device: Continuous Glucose Monitoring System (CGMS);   Behavioral: Food log
Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified August 2016

The Relationship Between Advanced Glycation Endproducts and Diabetes

Conditions:   Diabetic Retinopathy;   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   University of Colorado, Denver
Recruiting - verified August 2016

A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TTP273;   Drug: Placebo
Sponsor:   vTv Therapeutics
Active, not recruiting - verified August 2016

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exendin [9-39];   Drug: Placebo
Sponsor:   Diabeteszentrum Bad Lauterberg im Harz
Completed - verified August 2016

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo matching ertugliflozin;   Drug: Metformin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified August 2016

The Diabetes and Aquatic Training Study (DATS)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Other: Aerobic training;   Other: Combined training;   Other: Training placebo
Sponsor:   Hospital de Clinicas de Porto Alegre
Completed - verified August 2016

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance
Interventions:   Drug: Metformin;   Drug: saxagliptin;   Drug: AZD9668;   Drug: placebo
Sponsors:   Nick Giannoukakis, PhD;   National Institutes of Health (NIH);   University of Pittsburgh;   University of South Florida;   AstraZeneca
Recruiting - verified August 2016

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Device: MyStar DoseCoach
Sponsor:   Sanofi
Recruiting - verified August 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2016

Endocrine Regulation of Lipolysis in Obesity and Diabetes

Conditions:   Obesity;   Diabetes
Intervention:   Other: adipose tissue sampling
Sponsors:   Hasselt University;   Jessa Hospital
Completed - verified November 2015

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Active, not recruiting - verified August 2016

Meta Analysis of the Effect of a Low Glycemic Index Diet and Glycemic Load on Body Weight

Conditions:   Body Weight;   Obesity;   Cardiovascular Diseases;   Diabetes Mellitus, Type 2
Intervention:   Other: GI and/or GL
Sponsor:   University of Toronto
Active, not recruiting - verified November 2014

Incidence of Type 2 Diabetes in the di@Bet.es Study

Conditions:   Diabetes Mellitus, Type 2;   Metabolic Syndrome X
Intervention:  
Sponsors:   Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud;   Instituto de Salud Carlos III;   Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
Recruiting - verified August 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2016

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin;   Drug: Sulfonylurea
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2016

Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption

Condition:   Glucose Metabolism Disorder
Intervention:   Other: Diet soda containing aspartame only
Sponsor:   Rockefeller University
Recruiting - verified August 2016

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified August 2016

Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS

Condition:   Polycystic Ovary Syndrome
Intervention:  
Sponsor:   Ain Shams University
Recruiting - verified June 2016

Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: glargine + exenatide;   Drug: aspart 30
Sponsor:   Huazhong University of Science and Technology
Recruiting - verified August 2016

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2016

Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Diabetes
Intervention:   Biological: REMD-477
Sponsor:   REMD Biotherapeutics, Inc.
Recruiting - verified August 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

EndoBarrier TM Gastrointestinal Liner Diabetes Trial

Conditions:   Overweight and Obesity;   Diabetes
Interventions:   Device: EndoBarrier TM Gastrointestinal Liner;   Other: Best Medical Care
Sponsors:   Imperial College London;   National Institute for Health Research, United Kingdom;   University Hospital Southampton NHS Foundation Trust.;   Brunel University;   University of Surrey
Recruiting - verified March 2016

Community-based Adolescent Diabetes Prevention Program

Condition:   Pre-Diabetes
Intervention:   Behavioral: TEEN HEED
Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified August 2016

Ghrelin and Beta Cell Function in Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Synthetic human AG;   Drug: Arginine;   Drug: 0.9% saline solution
Sponsors:   Jenny Tong, MD, MPH;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified August 2016

Survivorship Promotion In Reducing IGF-1 Trial

Conditions:   Breast Cancer;   Prostate Cancer;   Lung Cancer;   Colon Cancer;   Melanoma of Skin;   Endometrial Cancer;   Liver Cancer;   Pancreatic Cancer;   Rectal Cancer;   Kidney Cancer;   Other Solid Malignant Tumors
Interventions:   Drug: Metformin;   Behavioral: Coach Directed Behavioral Weight Loss;   Behavioral: Self-control weight loss
Sponsor:   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2016

Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: Nutritional Counseling;   Other: Usual Diet Guidance
Sponsor:   Hospital de Clinicas de Porto Alegre
Recruiting - verified August 2016

Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Medication Adherence
Intervention:   Behavioral: Text Messaging
Sponsors:   Vanderbilt University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation - verified August 2016

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2016

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Chronic Kidney Disease;   Type 2 Diabetes
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Active, not recruiting - verified August 2016

Effects of Linagliptin on Endothelial Function

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   Medical University of Graz
Active, not recruiting - verified August 2016

Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy

Condition:   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Lobeglitazone;   Drug: Glimepirde;   Drug: Metformin
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2016

Mechanisms of Endothelial Dysfunction in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Biological: Blood samples
Sponsor:   University Hospital, Rouen
Recruiting - verified August 2016

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ipragliflozin
Sponsor:   Astellas Pharma Inc
Completed - verified August 2016

Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5 mg;   Drug: Placebo 5 mg for Saxagliptin;   Drug: Placebo 500 mg for metformin (with titration);   Drug: Metformin 500 mg with titration
Sponsor:   AstraZeneca
Completed - verified August 2016

Investigating the Role of the Polyol Pathway in the Central Nervous System

Condition:   Hyperglycemia
Interventions:   Other: Brain MRS during hyperglycemic clamp;   Other: Analysis of Metabolites in cerebrospinal fluid
Sponsor:   Yale University
Recruiting - verified August 2016

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Condition:   Coronary Artery Disease
Interventions:   Drug: Cilostazol;   Drug: Aspirin
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2016

Diabetes Effects on Long-Term Implant Survival and Success

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified August 2016

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Condition:   Insulin Sensitivity
Interventions:   Drug: Eritoran;   Other: D5W
Sponsor:   Nicolas Musi
Recruiting - verified August 2016

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2016

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Recruiting - verified August 2016

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified August 2016

The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration

Conditions:   Peripheral Neuropathy;   Obesity
Intervention:  
Sponsors:   University of Utah;   American Diabetes Association
Active, not recruiting - verified August 2016

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LIXISENATIDE AVE0010;   Drug: Sitagliptin;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Completed - verified August 2016

Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Triple combination
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified August 2016

The Effects of a Moderate Weight Loss on Insulin Resistance

Condition:   Insulin Resistance
Intervention:   Behavioral: Dietary consultations
Sponsors:   Yale University;   Howard Hughes Medical Institute
Recruiting - verified August 2016

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified August 2016

Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)

Condition:   Insulin Sensitivity
Interventions:   Drug: Maltodextrin;   Drug: Synbiotic;   Drug: Sevelamer
Sponsors:   The University of Texas Health Science Center at San Antonio;   American Diabetes Association
Recruiting - verified August 2016

Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children

Conditions:   Overweight;   Obesity
Interventions:   Dietary Supplement: Prebiotic fiber;   Dietary Supplement: Placebo
Sponsors:   University of Calgary;   Alberta Children's Hospital
Active, not recruiting - verified August 2016

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Condition:   Healthy
Interventions:   Biological: HEPLISAV;   Biological: Engerix-B
Sponsor:   Dynavax Technologies Corporation
Completed - verified August 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified August 2016

Use of Sitagliptin to Decrease Microalbuminuria

Conditions:   Type 2 Diabetes;   Microalbuminuria
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsor:   University of Missouri-Columbia
Terminated - verified August 2016

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: Mk-8521;   Drug: Placebo;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: MK-8521;   Drug: Placebo;   Drug: Placebo;   Drug: MK-8521;   Drug: MK-8521;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2016

Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound

Conditions:   Hepatitis C;   Hepatitis B;   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Intervention:   Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified July 2016

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2016

Insulin Resistance in the Control of Intestinal Lipid Metabolism

Conditions:   Insulin Resistance;   Type 2 Diabetes
Intervention:   Behavioral: taste tests
Sponsor:   University of Missouri-Columbia
Completed - verified August 2016

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified August 2016

Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients

Conditions:   Diabetes Mellitus Type 2;   Non-alcoholic Fatty Liver Disease;   Obesity
Interventions:   Drug: Amlexanox;   Drug: Placebo
Sponsor:   University of Michigan
Active, not recruiting - verified August 2016

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified August 2016

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (10 mg);   Drug: Placebo to Ertuglifozin;   Drug: Metformin;   Drug: Placebo to Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed - verified August 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Conditions:   Type 2 Diabetes Mellitus;   Hypertension;   Endothelial Dysfunction
Interventions:   Drug: Glibenclamide;   Drug: Vildagliptin
Sponsors:   Dr. José Fernando Vilela-Martin MD PhD;   Novartis
Completed - verified August 2016

Mechanisms of Diabetic Kidney Disease in American Indians

Conditions:   Nervous System;   Diabetic Kidney Disease;   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrolling by invitation - verified August 2016

Effect of Chronic Incretin-based Therapy in Cystic Fibrosis

Conditions:   Cystic Fibrosis;   Pancreatic Insufficiency
Intervention:   Drug: Sitagliptin
Sponsors:   University of Pennsylvania;   Children's Hospital of Philadelphia
Recruiting - verified August 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Amlexanox for Type 2 Diabetes and Obesity

Conditions:   Diabetes Mellitus Type 2;   Non Alcoholic Fatty Liver Disease;   Obesity
Intervention:   Drug: Amlexanox
Sponsor:   University of Michigan
Active, not recruiting - verified August 2016

Diabetes Prevention in Clinical Practice.

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Low intensity intervention;   Behavioral: High intensity intervention.
Sponsor:   Göteborg University
Completed - verified August 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2016

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified August 2016

Type 2 Diabetes and Exercise Function in Single Leg Exercises

Condition:   Type 2 Diabetes
Intervention:   Other: Single Leg Exercise Training
Sponsor:   University of Colorado, Denver
Recruiting - verified August 2016

Better Diabetes Control, Quality - Educate to Achieve Compliance.

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified August 2016

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified August 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2016

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified August 2016

Barriers to Physical Activity in People With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Placebo Attention Control;   Other: Supervised Exercise Training
Sponsors:   University of Colorado, Denver;   Colorado Clinical & Translational Sciences Institute
Recruiting - verified July 2016

Exercise, Glucose Kinetics, and the Incretin Effect

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Exercise
Sponsor:   Rigshospitalet, Denmark
Completed - verified August 2016

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Conditions:   Diabetic Retinopathy;   HIV
Interventions:   Drug: Tesamorelin;   Drug: Placebo-Control
Sponsor:   Theratechnologies
Recruiting - verified August 2016

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

Condition:   HIV
Intervention:   Drug: Tesamorelin for injection
Sponsor:   Theratechnologies
Recruiting - verified August 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2016

Physical and Cognitive Function - Look AHEAD Ancillary Study

Conditions:   Diabetes;   Weight Loss;   Physical Function;   Cognitive Function
Interventions:   Behavioral: Lifestyle intervention;   Behavioral: Diabetes Support Education
Sponsors:   Wake Forest University;   Pennington Biomedical Research Center;   University of Colorado, Denver;   University of Tennessee;   University of Pittsburgh
Completed - verified August 2016

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified August 2016

Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 2016

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

Conditions:   Type 2 Diabetes;   Obesity;   Bariatric Surgery
Intervention:  
Sponsor:   University of Pennsylvania
Completed - verified August 2016

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Placebo
Sponsors:   University Hospital, Caen;   Eli Lilly and Company
Recruiting - verified July 2016

Surgery Or Lifestyle Intervention for Type 2 Diabetes (SOLID)

Condition:   Type 2 Diabetes
Interventions:   Procedure: Roux-en-Y Gastric Bypass surgery;   Procedure: Laparoscopic Adjustable Gastric Banding surgery;   Behavioral: Intensive Lifestyle Modification
Sponsors:   University of Pennsylvania;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 2016

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified August 2016

Longitudinal Cohort Study Comparing 2 Surgical Techniques in Patients With Class 3 Obesity and Type 2 Diabetes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Procedure: Roux-en-Y gastric bypass;   Procedure: Adjustable gastric band
Sponsor:   University Hospital, Lille
Completed - verified August 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified August 2016

Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

Conditions:   Type 2 Diabetes Mellitus;   Nephropathy
Interventions:   Drug: Valsartan;   Drug: Placebo;   Drug: Probucol
Sponsor:   Guangdong General Hospital
Active, not recruiting - verified August 2016

A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK0941;   Drug: Comparator: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2016

A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Ethanol
Sponsor:   Hoffmann-La Roche
Terminated - verified August 2016

Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

Condition:   Non-Insulin Dependent Diabetes Mellitus
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified August 2016

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Comparator: sitagliptin 100 mg;   Drug: Comparator: sitagliptin 200 mg;   Drug: Comparator: placebo;   Drug: Comparator: pioglitazone
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2016

Study of Ro 205-2349 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes
Intervention:   Drug: Ro 205-2349
Sponsor:   Hoffmann-La Roche
Completed - verified August 2016